257 related articles for article (PubMed ID: 28389388)
21. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins.
Regaya I; Beeton C; Ferrat G; Andreotti N; Darbon H; De Waard M; Sabatier JM
J Biol Chem; 2004 Dec; 279(53):55690-6. PubMed ID: 15498765
[TBL] [Abstract][Full Text] [Related]
22. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
23. Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation.
Jin L; Pan Y; Pham AC; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2021 Mar; 110(3):1182-1188. PubMed ID: 33065128
[TBL] [Abstract][Full Text] [Related]
24. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
Edwards W; Fung-Leung WP; Huang C; Chi E; Wu N; Liu Y; Maher MP; Bonesteel R; Connor J; Fellows R; Garcia E; Lee J; Lu L; Ngo K; Scott B; Zhou H; Swanson RV; Wickenden AD
J Biol Chem; 2014 Aug; 289(33):22704-22714. PubMed ID: 24939846
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
26. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
27. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
Rashid MH; Kuyucak S
J Phys Chem B; 2014 Jan; 118(3):707-16. PubMed ID: 24397610
[TBL] [Abstract][Full Text] [Related]
28. A four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom.
Lebrun B; Romi-Lebrun R; Martin-Eauclaire MF; Yasuda A; Ishiguro M; Oyama Y; Pongs O; Nakajima T
Biochem J; 1997 Nov; 328 ( Pt 1)(Pt 1):321-7. PubMed ID: 9359871
[TBL] [Abstract][Full Text] [Related]
29. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.
Varga Z; Gurrola-Briones G; Papp F; Rodríguez de la Vega RC; Pedraza-Alva G; Tajhya RB; Gaspar R; Cardenas L; Rosenstein Y; Beeton C; Possani LD; Panyi G
Mol Pharmacol; 2012 Sep; 82(3):372-82. PubMed ID: 22622363
[TBL] [Abstract][Full Text] [Related]
30. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
31. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
32. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and characterization of Pi4, a scorpion toxin from Pandinus imperator that acts on K+ channels.
M'Barek S; Mosbah A; Sandoz G; Fajloun Z; Olamendi-Portugal T; Rochat H; Sampieri F; Guijarro JI; Mansuelle P; Delepierre M; De Waard M; Sabatier JM
Eur J Biochem; 2003 Sep; 270(17):3583-92. PubMed ID: 12919322
[TBL] [Abstract][Full Text] [Related]
34. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
[TBL] [Abstract][Full Text] [Related]
35. Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.
Li Z; Liu WH; Han S; Peng BW; Yin J; Wu YL; He XH; Li WX
J Biol Chem; 2012 Aug; 287(35):29479-94. PubMed ID: 22761436
[TBL] [Abstract][Full Text] [Related]
36. The voltage-gated potassium channel K
Tajti G; Wai DCC; Panyi G; Norton RS
Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
[TBL] [Abstract][Full Text] [Related]
37. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Gurrola GB; Hernández-López RA; Rodríguez de la Vega RC; Varga Z; Batista CV; Salas-Castillo SP; Panyi G; del Río-Portilla F; Possani LD
Biochemistry; 2012 May; 51(19):4049-61. PubMed ID: 22540187
[TBL] [Abstract][Full Text] [Related]
38. Solution structure of IsTX. A male scorpion toxin from Opisthacanthus madagascariensis (Ischnuridae).
Yamaji N; Dai L; Sugase K; Andriantsiferana M; Nakajima T; Iwashita T
Eur J Biochem; 2004 Oct; 271(19):3855-64. PubMed ID: 15373831
[TBL] [Abstract][Full Text] [Related]
39. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Beeton C; Wulff H; Standifer NE; Azam P; Mullen KM; Pennington MW; Kolski-Andreaco A; Wei E; Grino A; Counts DR; Wang PH; LeeHealey CJ; S Andrews B; Sankaranarayanan A; Homerick D; Roeck WW; Tehranzadeh J; Stanhope KL; Zimin P; Havel PJ; Griffey S; Knaus HG; Nepom GT; Gutman GA; Calabresi PA; Chandy KG
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17414-9. PubMed ID: 17088564
[TBL] [Abstract][Full Text] [Related]
40. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
Takacs Z; Toups M; Kollewe A; Johnson E; Cuello LG; Driessens G; Biancalana M; Koide A; Ponte CG; Perozo E; Gajewski TF; Suarez-Kurtz G; Koide S; Goldstein SA
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22211-6. PubMed ID: 20007782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
